Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 21, 2024 08:00 ET | Source: TearSolutions, Inc.

TearSolutions, Inc. Secures $3M Series B Funding

New Capital Boosts Efforts to Address Rare Corneal Disease Funding Highlights Growing Interest in Untapped Rare Corneal Conditions CHARLOTTESVILLE, Va., Nov. 21, 2024 (GLOBE NEWSWIRE) --...
April 03, 2024 06:00 ET | Source: TearSolutions, Inc.

TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors

CHARLOTTESVILLE, Va., April 03, 2024 (GLOBE NEWSWIRE) -- TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED)...
November 01, 2023 06:00 ET | Source: TearSolutions, Inc.

TearSolutions, Inc. Appoints Robert Dempsey to its Board of Directors

CHARLOTTESVILLE, Va., Nov. 01, 2023 (GLOBE NEWSWIRE) -- TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED)...
March 07, 2023 06:00 ET | Source: TearSolutions, Inc.

TearSolutions Expands and Establishes Advisory Boards and Strengthens Leadership Team

CHARLOTTESVILLE, Va., March 07, 2023 (GLOBE NEWSWIRE) -- TearSolutions, Inc. a privately held clinical-stage ophthalmic biopharmaceutical company focused on developing a potentially disruptive...
February 14, 2022 05:00 ET | Source: TearSolutions, Inc.

TearSolutions, Inc. Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Lacripep™

CHARLOTTESVILLE, Va., Feb. 14, 2022 (GLOBE NEWSWIRE) -- TearSolutions, Inc. (“the Company”), a privately held developer of a replacement therapy for the treatment of Dry Eye Disease (DED) called...